Overview
Pontocerebellar hypoplasia type 5 (PCH5) is an extremely rare and severe neurodegenerative disorder characterized by pronounced underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. PCH5 is distinguished from other forms of pontocerebellar hypoplasia by its prenatal onset with fetal seizures, and it presents at birth with severe encephalopathy, profound intellectual disability, and seizures that are often intractable. Affected infants typically exhibit microcephaly, spasticity, and minimal voluntary movement. The condition has been associated with mutations in the TSEN54 gene, which encodes a subunit of the tRNA splicing endonuclease complex, linking it molecularly to several other PCH subtypes. Clinically, PCH5 affects the central nervous system profoundly. Neuroimaging reveals severe cerebellar and pontine hypoplasia, with a characteristic "dragonfly" or "butterfly" appearance of the cerebellum on MRI due to preferential involvement of the cerebellar hemispheres relative to the vermis. Affected neonates may present with respiratory difficulties, feeding problems, and opisthotonus. Fetal seizures, which may be detected prenatally, are a hallmark feature that helps distinguish PCH5 from other PCH subtypes. The prognosis is extremely poor, with most affected individuals dying in the neonatal period or early infancy. There is currently no curative treatment for PCH5. Management is entirely supportive and palliative, focusing on seizure control with anticonvulsant medications, nutritional support (often via nasogastric or gastrostomy tube feeding), respiratory support, and physical therapy. Genetic counseling is recommended for affected families. Research into the molecular mechanisms underlying tRNA splicing endonuclease complex dysfunction continues, but no disease-modifying therapies are available at this time.
Also known as:
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for Pontocerebellar hypoplasia type 5.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Pontocerebellar hypoplasia type 5 at this time.
New trials open frequently. Follow this disease to get notified.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Pontocerebellar hypoplasia type 5.
Community
No community posts yet. Be the first to share your experience with Pontocerebellar hypoplasia type 5.
Start the conversation →Latest news about Pontocerebellar hypoplasia type 5
No recent news articles for Pontocerebellar hypoplasia type 5.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Pontocerebellar hypoplasia type 5
What is Pontocerebellar hypoplasia type 5?
Pontocerebellar hypoplasia type 5 (PCH5) is an extremely rare and severe neurodegenerative disorder characterized by pronounced underdevelopment (hypoplasia) of the pons and cerebellum — structures in the brainstem and hindbrain critical for motor coordination, balance, and many autonomic functions. PCH5 is distinguished from other forms of pontocerebellar hypoplasia by its prenatal onset with fetal seizures, and it presents at birth with severe encephalopathy, profound intellectual disability, and seizures that are often intractable. Affected infants typically exhibit microcephaly, spasticity
How is Pontocerebellar hypoplasia type 5 inherited?
Pontocerebellar hypoplasia type 5 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does Pontocerebellar hypoplasia type 5 typically begin?
Typical onset of Pontocerebellar hypoplasia type 5 is neonatal. Age of onset can vary across affected individuals.
Which specialists treat Pontocerebellar hypoplasia type 5?
1 specialists and care centers treating Pontocerebellar hypoplasia type 5 are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.